Diversa Corporation

Bioatla, Inc.

Verenium Corporation

Stratagene

Basf Enzymes LLC

Iphenotype LLC

Syngenta Participations Ag

Invitrogen Corporation

Bioalta, LLC

Bp Corporation North America Inc.

Femta Pharmaceuticals, Inc.

Other

Exuma Biotech Corp.

Union Bank of California, N.a.

Jay Milton Short

Gerhard Johann Frey

Hwai Wen Chang

Eric J Mathur

Toby Howard Richardson

Kevin A Gray

Walter Callen

Mark Joseph Burk

Dan Eric Robertson

Grace DeSantis

David Paul Weiner

Carl A Miller

Aileen Milan

Martin Kazaoka

Nelson Robert Barton

Martin Keller

Janne Samuli Kerovuo

Malgorzata Slupska

Kelvin Wong

Kelly Chatman

Ellen Chi

Eileen O'Donoghue

Keith A Kretz

Jennifer Ann Chaplin

James B Garrett

Mark Madden

Robert Farwell

Joseph A Sorge

Steve Briggs

William Michael Lafferty

Darcy Madden, Legal Representative

Tsotne David Djavakhishvili

Patricia L Kretz

John H Reid

William D Huse

William James Boyle

David E Lam

Lishan Zhao

Ronald V Swanson

Dennis Murphy

Bin Han

Bob Farwell

Grace Desantis

Mark (deceased) Madden

Matgorzata Slupska

Tim S Hitchman

David M Weiner

Edward J Bylina

Paul S Zorner

Gregory Ian Frost

James Joseph Onuffer, Jr

Anna Kosmotka

Steven Link

W Michael Lafferty

Catherine Pujol

Patrick V Warren

Anthony M Maffia

William Baum

Kevin Chow

Marcy Madden, Legal Representative

Eileen O'donoghue

Carl Miller

Gregory Frost

Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.

Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof

An antibody or antigen-binding antibody fragment having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 antigen, as well as immunoconjugates containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 antigen, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof

The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.

Chimeric antigen receptors against AXL or ROR2 and methods of use thereof

Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.

Conditionally active biological proteins

The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.

Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.

Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof

A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof

Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.

An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.

Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.

Conditionally active polypeptides and methods of generating them

This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

Mirac proteins

The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.

Methods of protein evolution

This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.

Conditionally active chimeric antigen receptors for modified T-cells

A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof

A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.

Conditionally active polypeptides

Growing community of inventors

Del Mar, CA, United States of America

Jay Milton Short